TMED3 expression is strongly up-regulated in several cancer types (including osteosarcoma, breast cancer, chordoma, HCC and non-small cell lung cancer (NSCLC)) and correlates with poor prognosis in patients [54,55,56,57,121]. Here, TMED3 is linked to hepatocellular carcinoma.